Cell Therapy News Volume 25.24 | Jul 29 2024

    0
    91








    2024-07-29 | CTN 25.23


    Cell Therapy News by STEMCELL Technologies
    Vol. 25.23 – 29 July, 2024
    TOP STORY

    C-JUN Overexpressing CAR-T Cells in Acute Myeloid Leukemia: Preclinical Characterization and Phase I Trial

    Scientists found that CAR T cells exposed to myeloid leukemia showed impaired activation and cytolytic function, accompanied by impaired antigen receptor downstream calcium, ZAP70, ERK, and C-JUN signaling, compared to those exposed to B cell leukemia.
    [Nature Communications]

    Full Article
    PUBLICATIONSListed by the impact factor of the journal

    Programmable Bacteria with Dynamic Virulence Modulation System for Precision Antitumor Immunity

    A genetically encoded microbial activation strategy was reported that used tunable and dynamic expression of surface extracellular polysaccharides to improve bacterial biocompatibility while retaining therapeutic efficacy.
    [Advanced Science]

    Full Article

    Surface Nanocoating of Bacteria as a Versatile Platform to Develop Living Therapeutics

    The authors used interfacial self-assembly to prepare lipid membrane-coated bacteria, exhibiting increased resistance against a variety of harsh environmental conditions owing to the nanocoating’s protective capability.
    [Nature Protocols]

    Abstract

    Lipid Nanoparticle-mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response

    Researchers showed that LNP-mRNA engineered dendritic cells could vaccinate recipient mice. Vaccinated mice showed strong anti-tumor T cell responses, rejected tumor challenge, and displayed no evidence of toxicity.
    [Small Methods]

    Full Article

    Proton Radiation Boosts the Efficacy of Mesothelin-Targeting Chimeric Antigen Receptor T Cell Therapy in Pancreatic Cancer

    The authors showed that proton radiation therapy increased mesothelin expression, modulated the immunosuppressive microenvironment, and improved the antitumor response of CAR T therapy, underscoring the transformative potential of this strategy.
    [Proceedings of The National Academy of Sciences of The United States of America]

    Full Article

    rhIL-7-hyFc, a Long-Acting Interleukin-7, Improves Efficacy of CAR-T Cell Therapy in Solid Tumors

    CAR-T cells targeting GPC2, GPC3, and MSLN were used in combination with NT-I7 to assess the anticancer activity.
    [Journal For Immunotherapy of Cancer]

    Abstract

    Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells

    Scientists reported that IFNγ, a potent immunomodulator secreted in the tumor microenvironment, could induce α2,6 hypersialylation in cancer cell lines derived from various histologies.
    [Cancer Immunology Research]

    Abstract

    Generation of Antitumor Chimeric Antigen Receptors Incorporating T Cell Signaling Motifs

    The authors developed chimeric adaptor proteins and CAR tyrosine kinases in which the intracellular ζ T cell receptor (TCRζ) chain was replaced with intracellular protein domains to stimulate signaling downstream of the TCRζ chain.
    [Science Signaling]

    Abstract

    Impulse Initiation in Engrafted Pluripotent Stem Cell-Derived Cardiomyocytes Can Stimulate the Recipient Heart

    Researchers experimentally studied whether impulse generation by transplanted cardiomyocytes could propagate to the host myocardium and overdrive the recipient rhythm.
    [Stem Cell Reports]

    Full Article
    Human whole peripheral blood for your large-scale studies. Click to learn more.
    REVIEWS

    Genetically Engineered Hypoimmunogenic Cell Therapy

    The authors discuss key advances and challenges in the clinical translation of hypoimmunogenic cells and describe the genetic engineering methods and manufacturing processes used to create hypoimmunogenic therapeutic cells, while highlighting the complexity of relevant immunological pathways.
    [Nature Reviews Bioengineering]

    Abstract

    In Utero Gene Therapy and its Application in Genetic Hearing Loss

    For major alpha thalassemia and severe osteogenesis imperfecta, in utero stem cell transplantation has entered the Phase I clinical trial stage.
    [Advanced Biology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy

    Anixa Biosciences, Inc. announced that its collaborator, Moffitt Cancer Center (Moffitt), has received approval by the FDA of an individual patient Investigational New Drug Application to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment.
    [Targeted Oncology]

    Press Release

    Retraction Notices Are Getting Clearer — but Progress Is Slow

    Retraction notices — the explanatory statements published alongside papers that have been withdrawn from the literature — have become more clearly worded and easier to access in some cases, according to a study that looked at hundreds of these notices.
    [Nature]

    Editorial
    FEATURED EVENT

    ECI 2024

    September 1 – 4, 2024
    Dublin, Ireland

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Research Associate – Identity of Mesenchymal Cells

    The Cambridge Stem Cell Institute – Cambridge, England, United Kingdom

    Postdoctoral Research Associate – Stem Cell Biology and Wound Healing

    The University of Edinburgh – Edinburgh, Scotland, United Kingdom

    PhD Positions – Cellular and Molecular Biophysics Group

    Max Planck Institute – Planegg, Germany

    Supervisor – Cell Therapy Manufacturing

    ElevateBio – Waltham, Massachusetts, United States

    Research Associate – CAR-Treg Therapy

    University of British Columbia – Vancouver, British Columbia, Canada

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2